Skip to main content
KLRA
NASDAQ Life Sciences

Bain Capital Affiliate Discloses 20.3% Stake in Kailera Therapeutics Post-IPO, Plans Active Role

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Positive
Importance info
8
Price
$24.91
Mkt Cap
$3.249B
52W Low
$23.65
52W High
$28.227
Market data snapshot near publication time

summarizeSummary

BCPE Perseus Investor, LP, an affiliate of Bain Capital, has disclosed a 20.3% beneficial ownership stake in Kailera Therapeutics following its IPO, signaling active involvement in the company's strategic direction.


check_boxKey Events

  • Significant Post-IPO Stake

    BCPE Perseus Investor, LP, an affiliate of Bain Capital, now beneficially owns 26,255,581 shares, representing 20.27% of Kailera Therapeutics' common stock.

  • Substantial Investment

    The stake includes a purchase of 8,398,438 shares at the IPO price of $16.00 per share on April 20, 2026, for a total of $134,375,008. This follows the conversion of prior preferred stock holdings.

  • Active Investor Role

    The reporting person intends to take an active role in working with the Issuer's management and Board on operational, financial, and strategic initiatives. Andrew Kaplan, a Partner of Bain Capital Investors, LLC, is a member of the Issuer's board of directors.

  • Lock-Up Agreement

    The investor is subject to a 180-day lock-up agreement, restricting the sale or transfer of shares post-IPO, demonstrating commitment.


auto_awesomeAnalysis

This Schedule 13D filing reveals that BCPE Perseus Investor, LP, an affiliate of Bain Capital, now beneficially owns 20.3% of Kailera Therapeutics' common stock. This significant stake was established through the conversion of preferred stock and a post-IPO purchase of 8.4 million shares at the IPO price of $16.00, totaling over $134 million. The filing indicates that Bain Capital intends to take an active role in the company's operational, financial, and strategic initiatives, reinforced by Andrew Kaplan, a Bain Capital Partner, serving on the board. This disclosure provides crucial insight into the post-IPO ownership structure and the influence of a major institutional investor, suggesting a strong vote of confidence and potential strategic guidance for the newly public company. The lock-up agreement for 180 days further demonstrates commitment.

At the time of this filing, KLRA was trading at $24.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $23.65 to $28.23. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed KLRA - Latest Insights

KLRA
Apr 23, 2026, 8:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
KLRA
Apr 23, 2026, 7:34 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
KLRA
Apr 20, 2026, 6:10 PM EDT
Filing Type: 4
Importance Score:
9
KLRA
Apr 20, 2026, 6:08 PM EDT
Filing Type: 4
Importance Score:
9
KLRA
Apr 20, 2026, 6:01 PM EDT
Filing Type: 4
Importance Score:
9
KLRA
Apr 20, 2026, 6:00 PM EDT
Filing Type: 4
Importance Score:
9
KLRA
Apr 20, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
9
KLRA
Apr 17, 2026, 4:06 PM EDT
Filing Type: 424B4
Importance Score:
9
KLRA
Apr 16, 2026, 7:25 PM EDT
Source: GlobeNewswire
Importance Score:
9